Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Veracyte Inc (VCYT): Are Hedge Funds Right About This Stock?

Page 1 of 2

The successful funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary to beat the market. That’s why we pay close attention to what they think in small cap stocks. In this article, we take a closer look at Veracyte Inc (NASDAQ:VCYT) from the perspective of those successful funds.

 VCYT investors should be aware of an increase in hedge fund sentiment of late. There were 7 hedge funds in our database with VCYT holdings at the end of the previous quarter, versus 8 at the end of Q3. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Flex Pharma Inc (NASDAQ:FLKS), Black Box Corporation (NASDAQ:BBOX), and DRDGOLD Ltd. (ADR) (NYSE:DRD) to gather more data points.

Follow Veracyte Inc. (NASDAQ:VCYT)
Trade (NASDAQ:VCYT) Now!

We follow over 700 hedge funds and other institutional investors and by analyzing their quarterly 13F filings, we identify stocks that they are collectively bullish on and develop investment strategies based on this data. One strategy that outperformed the market over the last year involves selecting the 100 best-performing funds and identifying the 30 mid-cap stocks that they are collectively most bullish on. Over the past year, this strategy generated returns of 18%, topping the 8% gain registered by S&P 500 ETFs. We launched this strategy 2.5 years ago and it returned more than 39% since then, vs. 22% gain registered by the S&P 500 ETFs.

doctor, smiling, group, medical, leadership, ethnicity, standing, background, uniform, care, crowd, on, row, surgeon, practitioner, adult, out, people, skill, black, female,

g-stockstudio/Shutterstock.com

Now, let’s view the key action encompassing Veracyte Inc (NASDAQ:VCYT).

Hedge fund activity in Veracyte Inc (NASDAQ:VCYT)

At Q3’s end, a total of 8 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 14% from one quarter earlier. On the other hand, there were a total of 11 hedge funds with a bullish position in VCYT at the beginning of this year. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of notable hedge fund managers who were boosting their stakes significantly (or already accumulated large positions).

VCYT Chart

Of the funds tracked by Insider Monkey, venBio Select Advisor holds the most valuable position in Veracyte Inc (NASDAQ:VCYT). venBio Select Advisor has a $7 million position in the stock, comprising 1.2% of its 13F portfolio. On venBio Select Advisor’s heels is Cannell Capital, led by J. Carlo Cannell, holding a $2.9 million position; the fund has 1.2% of its 13F portfolio invested in the stock. Remaining peers that are bullish consist of Ken Greenberg and David Kim’s Ghost Tree Capital, Millennium Management, one of the 10 largest hedge funds in the world, and Jim Simons’ Renaissance Technologies. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2